NTRK1 and myeloid sarcoma: In addition to imatinib, a number of tyrosine kinase inhibitors, approved for cancer treatment and targeting the Abl- and other non-receptor tyrosine kinases, are available and could be potential drug candidates for MS; dasatinib was shown to reduce disease in the initial phase of EAE in mice (Azizi et al., 2015); bosutinib (Golas et al., 2003); and the more Abl specific tyrosine kinase inhibitors nilotinib (Weisberg et al., 2005) and ponatinib (Huang et al., 2010) have not yet been reported for clinical studies in EAE or MS.